Type 2 diabetes is one of the most common chronic diseases, affecting hundreds of millions of people worldwide. While lifestyle changes and oral medications have long been the standard treatment, many patients struggle to keep their blood sugar levels well controlled over time as the disease progresses. In recent years however, new injectable drug classes called Glucagon Like Peptide 1 (GLP-1) receptor agonists, or GLP-1 analogs, have emerged as a highly effective option for managing blood ... Read more
The Glucagon Like Peptide 1 Analogs market consists of injectable drugs that mimic the action of glucagon-like peptide-1 hormone. Glucagon like peptide 1 analogs are an innovative class of drugs for the treatment of type 2 diabetes that work differently than other oral hypoglycemic agents. They stimulate insulin secretion from the pancreas, suppress glucagon secretion, slow gastric emptying and increase feelings of satiety or fullness after meals.
